TABLE 79Mean costs and outcomes (percentile-based 95% CIs) for HCV/HIV co-infected patients using peginterferon alfa-2b and ribavirin combination therapy, from PSA

GenotypeTreatmentLifetime costs (£)QALYs
Genotypes 1 + 4BSC22,175 (15,557 to 30,351)12.70 (11.89 to 13.51)
PEG α-2b30,086 (24,839 to 36,244)13.37 (12.66 to 14.07)
Incremental7910 (5593 to 9673)0.66 (0.32 to 1.06)
Genotypes 2 + 3BSC22,010 (15,706 to 30,199)12.70 (11.85 to 13.56)
PEG α-2b25,105 (21,202 to 30,212)14.06 (13.26 to 14.85)
Incremental3095 (−1241 to 6340)1.36 (0.69 to 2.01)

PEG α, peginterferon alfa.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.